EMA Authorised: Nerlynx (neratinib) — Pierre Fabre Medicament

View source ↗

Summary

The European Medicines Agency authorised Nerlynx (neratinib) for breast cancer indications, under the marketing authorization holder Pierre Fabre Medicament. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nerlynx (neratinib)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Pierre Fabre Medicament. Decision date: 22/05/2025